Avrobio (AVRO) Receives a Buy from Berenberg Bank


In a report released today, Yun Zhong from Berenberg Bank maintained a Buy rating on Avrobio (AVRO), with a price target of $27.00. The company’s shares closed last Friday at $16.23.

According to TipRanks.com, Zhong is ranked #6173 out of 7087 analysts.

Currently, the analyst consensus on Avrobio is a Strong Buy with an average price target of $32.00, which is a 96.9% upside from current levels. In a report issued on November 5, Mizuho Securities also reiterated a Buy rating on the stock with a $35.00 price target.

See today’s analyst top recommended stocks >>

Based on Avrobio’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $36.78 million. In comparison, last year the company had a GAAP net loss of $17.15 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Avrobio, Inc. engages in the development of lentiviral-based gene therapies. It focuses on gene therapy for fabry, gaucher, pompe disease, and cystinosis. These gene therapies, on which the company was founded, were developed by Dr. Jeffrey Medin and Dr. Christopher Paige at the University Health Network. AvroBio launched in 2015, is headed by Co-Founder, President and CEO Geoff Mackay, and is headquartered in Cambridge, MA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts